Zenotech Laboratories Ltd Stock Price Today (NSE: ZENOTECH)
Fundamental Score
Zenotech Laboratories Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Zenotech Laboratories Ltd share price today is ₹46.73, up +4.54% on NSE/BSE as of 17 June 2026. Zenotech Laboratories Ltd (ZENOTECH) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹294.77 (Cr). The 52-week high for ZENOTECH share price is ₹67.00 and the 52-week low is ₹33.55. At a P/E ratio of 103.07x, ZENOTECH is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 4.81% and a debt-to-equity ratio of 0.00.
Zenotech Laboratories Ltd Share Price Chart — NSE/BSE Historical Performance
Zenotech Laboratories Ltd share price chart: 1.39% return over the past month. 52-week high ₹67.00, 52-week low ₹33.55.
Zenotech Laboratories Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹43.73 | ₹45.00 | ₹43.11 | ₹44.63 | 2.75K (Cr) | |
| ₹44.20 | ₹45.50 | ₹43.51 | ₹43.73 | 2.40K (Cr) | |
| ₹44.57 | ₹45.75 | ₹44.00 | ₹44.78 | 6.36K (Cr) | |
| ₹45.06 | ₹46.11 | ₹44.80 | ₹45.03 | 1.56K (Cr) | |
| ₹46.89 | ₹46.89 | ₹44.52 | ₹45.21 | 3.73K (Cr) | |
| ₹43.52 | ₹46.18 | ₹43.52 | ₹46.18 | 20.18K (Cr) | |
| ₹43.66 | ₹45.00 | ₹43.56 | ₹44.00 | 6.04K (Cr) | |
| ₹44.25 | ₹45.95 | ₹43.26 | ₹43.66 | 5.49K (Cr) | |
| ₹44.75 | ₹45.40 | ₹43.75 | ₹43.90 | 2.35K (Cr) | |
| ₹44.10 | ₹45.00 | ₹43.60 | ₹44.80 | 2.97K (Cr) |
Zenotech Laboratories Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹44.20 | ₹45.50 | ₹43.11 | ₹44.63 | +0.97% | |
| ₹44.00 | ₹48.00 | ₹42.90 | ₹44.78 | +1.77% | |
| ₹35.90 | ₹49.94 | ₹35.90 | ₹43.61 | +21.48% | |
| ₹44.61 | ₹46.80 | ₹33.55 | ₹34.29 | -23.13% | |
| ₹44.99 | ₹47.89 | ₹43.05 | ₹45.12 | +0.29% | |
| ₹46.99 | ₹50.93 | ₹43.01 | ₹44.76 | -4.75% | |
| ₹48.76 | ₹49.00 | ₹43.85 | ₹46.19 | -5.27% | |
| ₹49.90 | ₹53.50 | ₹47.50 | ₹48.65 | -2.51% | |
| ₹52.50 | ₹54.14 | ₹48.00 | ₹53.49 | +1.89% | |
| ₹55.75 | ₹57.90 | ₹48.55 | ₹52.50 | -5.83% | |
| ₹57.46 | ₹60.00 | ₹53.60 | ₹55.74 | -2.99% | |
| ₹65.40 | ₹67.00 | ₹55.50 | ₹56.69 | -13.32% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Zenotech Laboratories Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Zenotech Laboratories Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ZENOTECH across key market metrics for learning purposes.
Positive Indicators
5 factors identified
Strong Operating Margins (41.01%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Cash Generation (₹44.25 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (68.84%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
8 factors identified
Below-Average Return on Equity (4.81%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (9.40%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 103.07x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Profit Decline Concern (-224.14%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Weak Earnings Growth (0.36% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (0.36% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Limited Institutional Interest (FII+DII: 0.01%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Zenotech Laboratories Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Zenotech Laboratories Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Zenotech Laboratories LtdZenotech Labora...Selected✓ ZENOTECH • 532039 | 34/100 | ₹46.73₹47 | ₹294.77₹294.77 | 103.07Average 103.1 Average | 4.81%Poor 4.81% Poor | 9.40%Poor 9.40% Poor | 0.00Excellent 0.0 Excellent | 0.36%Average 0.36% Average | 10.59%Good 10.59% Good | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1780.10₹1780 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6596.50₹6597 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4339.90₹4340 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1398.70₹1399 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1267.50₹1268 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2249.80₹2250 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹1084.60₹1085 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2353.00₹2353 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1463.60₹1464 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5276.50₹5277 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Zenotech Laboratories Ltd PE Ratio History
Historical price-to-earnings ratio for ZENOTECH — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹0.92 | ₹46.19 | 50.2x |
| FY 2024 | ₹1.36 | ₹71.99 | 52.9x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Zenotech Laboratories Ltd Quarterly Performance
Latest quarterly metrics for ZENOTECH — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
14.94%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-224.14%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
10.59%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
0.36%
Compounded annual net profit growth over 5 years
Zenotech Laboratories Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for ZENOTECH — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Zenotech Laboratories Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Zenotech Laboratories Ltd (ZENOTECH) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Zenotech Laboratories Ltd
About ZENOTECH (Zenotech Laboratories Ltd)
Zenotech Laboratories Ltd is a pioneering pharmaceutical company deeply rooted in the vibrant Indian market. With a sharp focus on specialty generic injectables, ZENOTECH dedicates... its resources to the critical fields of oncology and anesthesiology, striving to deliver accessible and affordable solutions for patients in need. The company operates with a commitment to quality and innovation, constantly seeking to refine existing formulations and explore new avenues for therapeutic intervention. More than just a manufacturer, ZENOTECH is a partner in healthcare, understanding the evolving needs of clinicians and patients alike. Beyond its core product portfolio, ZENOTECH extends its expertise through comprehensive contract manufacturing services. Specializing in parenteral depot formulations, ophthalmic solutions, oncology treatments (both oral and injectable), and general injectables, the company offers tailored solutions to meet the unique requirements of its partners. ZENOTECH's state-of-the-art facilities and experienced team ensure the highest standards of quality and compliance throughout the manufacturing process. This dedication to excellence has established ZENOTECH as a trusted and reliable partner for pharmaceutical companies seeking to expand their reach and capabilities. ZENOTECH further leverages its assets through strategic leasing of its advanced biotech facility and equipment. This offering provides access to cutting-edge infrastructure for companies seeking to conduct research, development, or manufacturing activities. Complementing its core pharmaceutical offerings, ZENOTECH also provides essential supportive care products such as granulocyte-colony stimulating factor and granulocyte-macrophage colony-stimulating factor. Through its multifaceted approach, ZENOTECH Laboratories Ltd plays a vital role in advancing healthcare and fostering innovation within the pharmaceutical landscape.
Company Details
Key Leadership
Latest News
ZENOTECH Share Price: Frequently Asked Questions
What is the current share price of Zenotech Laboratories Ltd?
Zenotech Laboratories Ltd (ZENOTECH) trades at ₹46.73 on NSE and BSE. Market cap ₹294.77 (Cr). Educational data only.
What is the P/E ratio of Zenotech Laboratories Ltd?
Zenotech Laboratories Ltd has a P/E of 103.07x vs industry average 31.77x.
What is the Bull Run score for Zenotech Laboratories Ltd?
Zenotech Laboratories Ltd has a Bull Run score of 34/100 based on 25+ financial parameters.
Does Zenotech Laboratories Ltd pay dividends?
Zenotech Laboratories Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Zenotech Laboratories Ltd?
Zenotech Laboratories Ltd has ROE of 4.81%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Zenotech Laboratories Ltd?
Zenotech Laboratories Ltd has debt-to-equity of 0.00.
Is Zenotech Laboratories Ltd a good investment?
Bull Run gives Zenotech Laboratories Ltd a score of 34/100. This is not investment advice — consult a SEBI-registered advisor.